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OBJECTIVES: A telecommunications company, a founding
member of the Leapfrog Group, undertook this study to evalu-
ate its costs for retirees with Type-2 diabetes and the quality of
care received. METHODS: Health care costs were evaluated for
those with 6 months continuous enrollment prior to, and 12
months after, an initial Type 2 diabetes medical service noted in
a claims database. Vascular complications (cardio-, cerebro-,
micro- and peripheral) were grouped into a cohort hierarchy for
analysis. Cost differences were estimated among groups adjust-
ing for age, gender and severity of concurrent conditions.
RESULTS: The mean age of the population (N = 9959) was 74.4
years; 50% were female. Adjusted annual costs for those without
hospitalizations ranged from $4877 with no complications to
$12,271 with four complications. For those with hospitaliza-
tions, adjusted annual costs ranged from $18,839 with one com-
plication to $41,011 with 4 complications. Each group was
signiﬁcantly different (p < 0.001) from the no complication
group. Average annual costs per beneﬁciary with/without 
hospitalizations were cardiovascular (excluding hyperten-
sion), $11,128/$22,952; hypertension, $7656/$17,927; stroke,
$15,349/$25,333. No antidiabetic drug was present in 4360
(44%) beneﬁciaries in the 12-month period after the initial dia-
betes medical service. Of the 5599 prescribed an antidiabetic
drug, 2072 (37%) received a sulfonylurea only; 913 (16%)
received a sulfonylurea and metformin; 698 (12%) received met-
formin only; 566 (10%) received insulin only; and, 573 (10%)
received a thiazolidinedione alone or in combination. CON-
CLUSIONS: Type-2 diabetes produces signiﬁcant health care
expenditures by an employer, its retirees and Medicare. Despite
a generous prescription beneﬁt, drug treatment patterns suggest
misuse of agents with known adverse effects and underuse of
agents with evidence-based therapeutic beneﬁts. These results
will support a targeted, evidenced-based, employer-sponsored
intervention to improve quality-of-care and patient safety by
focusing on drug treatment appropriate for the individual’s 
circumstances.
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OBJECTIVE: To quantify the effect of diabetes-related hypo-
glycemia on direct health care costs and utilization. METHODS:
The sample consisted of 9162 privately insured employees that
had at least 12 months of continuous enrollment between
January 1, 1999 and December 31, 2001, and two or more pre-
scriptions for diabetes-related medications within the same ther-
apeutic class (insulin, sulfonylurea, or other oral diabetes-related
medication) from Medstat’s Health Productivity and Manage-
ment database. Patients were grouped into two cohorts: hypo-
glycemia or non-hypoglycemia depending on whether they
incurred a diagnosis of hypoglycemia (ICD-9-CM 250.8, 251.1,
251.2). The sample was further sub-set to those with claims for
insulin (N = 2664)—64% of the original sample. Data were gath-
ered starting from the ﬁrst evidence of a diabetes-related med-
ication. RESULTS: The incidence of hypoglycemia did not vary
signiﬁcantly by age, insurance type, or region of the country.
However, the hypoglycemia group had evidence of signiﬁcantly
increased comorbidity including renal disease (14% vs. 6%, 
p < 0.01), ophthalmic ﬁndings (42% vs. 30%, p < 0.01), and
neuropathy (30% vs. 15%, p < 0.01), as well as a higher 
mean Charlson Comorbidity Index (1.20 vs. 0.75, p < 0.01).
Hypoglycemia patients incurred on average twice as many hos-
pitalizations (1.0 vs. 0.5, p < 0.01) and emergency room visits
(0.8 vs. 0.4, p < 0.01) annually compared to insulin-users
without hypoglycemia. Forty percent (40%) of the excess hos-
pitalizations and 53% of the excess emergency room visits were
associated with a hypoglycemia diagnosis. Hypoglycemia
patients on insulin incurred twice the amount of overall health
care expenditures ($28,049 vs. $14,019, p < 0.01) and three
times the amount of diabetes-related health care expenditures
($14,590 vs. $5236, p < 0.01) compared to non-hypoglycemia
insulin users. CONCLUSION: Hypoglycemia contributed sig-
niﬁcantly to medical care utilization and health care expenditures
among patients using insulin. Analysis of the indirect costs
among this population as well as investigation into hypoglycemia
among diabetes patients on oral agents warrants further investi-
gation.
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OBJECTIVES: Diabetes disproportionately affects the poor and
medically underserved minorities, populations typically served
by State Medicaid programs. This study sought to assess the pat-
terns of diabetes-related health care costs incurred by the Texas
Medicaid program for Hispanics, African-Americans, and Cau-
casians with type-2 diabetes. METHODS: Treatment-naïve adult
patients in 2000 were identiﬁed. Total costs were assessed in the
12-months following the initiation of therapy, deﬁned as the ﬁrst
ﬁlling of a prescription following 6 months of no such prescrip-
tion. Patient demographic and disease severity measures as well
as county level variables were evaluated. To assess factors asso-
ciated with treatment cost, bivariate and multivariate linear
regression analyses were performed, where log transformed cost
was used as a dependent variable. RESULTS: Resource utiliza-
tion patterns and treatment costs of patients with type-2 diabetes
differ among the race and ethnic groups studied. In the ﬁrst year
of diabetes management, total treatment costs for Hispanics
($7189) and ($6715) were substantially lower than for white
patients ($8549). Although the difference in health care costs
between Caucasians and African-Americans was mostly
accounted for by demographic, clinical, and county level vari-
ability, the cost difference between Hispanics and Caucasians still
persisted with regard to these factors. CONCLUSIONS: The
immediate cost to care for patients with type-2 diabetes is 
substantial in this Medicaid population, regardless of race or 
ethnicity. Moreover, the differences in costs between the groups
are substantial, suggesting that race- or ethnicity-related factors
associated with persistence need to be addressed in optimizing
early therapy.
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OBJECTIVES: Painful neuropathy is a common complication of
diabetic patients. The purpose of this study is to compare the
cost-effectiveness of duloxetine to routine treatment in the 
